

Sub E1

35. (New) A method of treating a neoplasia in a mammal in accordance with claim 5, wherein said gene encodes a suicide enzyme.

36. (New) A method of treating a neoplasia in a mammal in accordance with claim 35, further comprising administering a prodrug.

Sub E1

37. (New) A method of treating a neoplasia in a mammal in accordance with claim 36, wherein said prodrug is administered after the serum stable nucleic acid-lipid particle.

38. (New) A method of treating a neoplasia in a mammal in accordance with claim 36, wherein said prodrug is administered before the serum stable nucleic acid-lipid particle.

39. (New) A method of treating a neoplasia in a mammal in accordance with claim 9, further comprising administering a chemotherapeutic agent.

40. (New) A method of treating a neoplasia in a mammal in accordance with claim 39, wherein the chemotherapeutic agent is administered after the serum stable nucleic acid-lipid particle.

41. (New) A method of treating a neoplasia in a mammal in accordance with claim 39, wherein the chemotherapeutic agent is administered before the serum stable nucleic acid-lipid particle.

42. (New) A method of treating a neoplasia in a mammal in accordance with claim 1, wherein the lipid portion comprises a cationic lipid and a neutral lipid.

Sub E1

43. (New) A method of treating a neoplasia in a mammal in accordance with claim 42, wherein the cationic lipid is DODAC.